Eton Pharmaceuticals/$ETON
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Eton Pharmaceuticals
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.
Ticker
$ETON
Sector
Primary listing
Employees
31
Headquarters
Website
ETON Metrics
BasicAdvanced
$527M
-
-$0.16
1.13
-
Price and volume
Market cap
$527M
Beta
1.13
52-week high
$23.00
52-week low
$7.58
Average daily volume
314K
Financial strength
Current ratio
1.773
Quick ratio
1.032
Long term debt to equity
116.443
Total debt to equity
128.096
Interest coverage (TTM)
0.50%
Profitability
EBITDA (TTM)
4.538
Gross margin (TTM)
63.44%
Net profit margin (TTM)
-7.10%
Operating margin (TTM)
3.36%
Effective tax rate (TTM)
-2.51%
Revenue per employee (TTM)
$1,880,000
Management effectiveness
Return on assets (TTM)
1.83%
Return on equity (TTM)
-22.06%
Valuation
Price to revenue (TTM)
8.939
Price to book
22
Price to tangible book (TTM)
-59.12
Price to free cash flow (TTM)
126.728
Free cash flow yield (TTM)
0.79%
Free cash flow per share (TTM)
0.155
Growth
Revenue change (TTM)
85.40%
Earnings per share change (TTM)
-39.91%
3-year revenue growth (CAGR)
52.51%
3-year earnings per share growth (CAGR)
-31.36%
What the Analysts think about ETON
Analyst ratings (Buy, Hold, Sell) for Eton Pharmaceuticals stock.
Bulls say / Bears say
On May 28, 2025, the FDA approved KHINDIVI™, the first and only hydrocortisone oral solution for pediatric adrenocortical insufficiency, with a commercial launch the week of June 2nd and expected combined peak sales of over $50 million alongside Alkindi Sprinkle (GlobeNewswire).
Eton’s inclusion in the Russell 2000® and Russell 3000® indexes effective June 27, 2025, is poised to attract passive index fund inflows, enhance institutional visibility, and improve share liquidity (GlobeNewswire).
The FDA accepted the NDA for ET-600, a desmopressin oral solution for central diabetes insipidus, assigning a February 25, 2026 target action date and securing patent protection through 2044, advancing Eton’s late-stage pipeline (Nasdaq).
The FDA postponed its PDUFA target action date for ET-400 by three months to May 28, 2025, indicating additional review was required and delaying potential hydrocortisone oral solution revenues (Nasdaq).
Despite strong revenue growth, Eton reported a GAAP net loss of $0.10 per share in Q2 2025 and incurred elevated G&A expenses of $7.6 million as launch investments weighed on profitability (GlobeNewswire).
First-quarter 2025 results included $3.3 million of non-recurring licensing revenue—$1.8 million recognized upfront from out-licensing INCRELEX—highlighting volatility in revenue streams once these one-time fees are exhausted (GlobeNewswire).
Data summarised monthly by Lightyear AI. Last updated on 9 Oct 2025.
ETON Financial Performance
Revenues and expenses
ETON Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Eton Pharmaceuticals stock?
Eton Pharmaceuticals (ETON) has a market cap of $527M as of October 12, 2025.
What is the P/E ratio for Eton Pharmaceuticals stock?
The price to earnings (P/E) ratio for Eton Pharmaceuticals (ETON) stock is 0 as of October 12, 2025.
Does Eton Pharmaceuticals stock pay dividends?
No, Eton Pharmaceuticals (ETON) stock does not pay dividends to its shareholders as of October 12, 2025.
When is the next Eton Pharmaceuticals dividend payment date?
Eton Pharmaceuticals (ETON) stock does not pay dividends to its shareholders.
What is the beta indicator for Eton Pharmaceuticals?
Eton Pharmaceuticals (ETON) has a beta rating of 1.13. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.